DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Plain language summaries

3 Interesting Facts about Plain Language Summaries

Did you know these 3 facts about plain language summaries?...

World Patient Safety Day September 17, 2021 – Safe Maternal and Newborn Care

This World Patient Safety Day, let's make maternal and newborn care a global health priority...
Strategic publication planning: A handy infographic for medical affairs

Strategic Publication Planning: Infographic for Medical Affairs

Here's a quick and easy-to-follow guide on for medical affairs teams on the what, how...
Pexels Alexander Suhorucov

Plain Language Summary Development in Japan: Current State and Challenges

This page contains supplementary information to support a poster presented at the Virtual 17th Annual...
Publication planning training

Publication Planning Training for Regional Medical Affairs Team

How a global pharma company overcame challenges of integration with regional teams in terms of...
Trends in publication review of articles

Review Article Publication Trends

This poster was presented by representatives from Cactus Life Sciences at the 11th Annual Meeting...

Learn more ABOUT our company.